Partner With OneThree

Together we can discover new medicines at an unprecedented scale by generating new insights to accelerate your internal R&D or identifying new therapeutics to fill your pipeline

Testimonials

"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work."
"I expect that this approach will be integral to the future of drug discovery."


Josh Allen, PhD
Chief Science Officer
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection." "We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
1_LS9stVp_IaCWeNp
Syed Kazmi
CEO, Jubilant Therapeutics
" We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."



Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier."

"The speed and applicability of this platform for drug discovery is unprecedented."




Paraskevi Giannakakou, PhD
Director of Lab Research (Heme/Onc), Weill Cornell
"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work."
"I expect that this approach will be integral to the future of drug discovery."
Josh Allen, PhD
Chief Science Officer
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection." "We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
1_LS9stVp_IaCWeNp
Syed Kazmi
CEO, Jubilant Therapeutics
" We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."
Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier."

"The speed and applicability of this platform for drug discovery is unprecedented."
Paraskevi Giannakakou, PhD
Director of Laboratory Research (Heme/Onc)
"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work."
"I expect that this approach will be integral to the future of drug discovery."
Josh Allen, PhD
Chief Science Officer
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection." "We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
1_LS9stVp_IaCWeNp
Syed Kazmi
CEO, Jubilant Therapeutics
" We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."
Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier."

"The speed and applicability of this platform for drug discovery is unprecedented."
Paraskevi Giannakakou, PhD
Director of Laboratory Research (Heme/Onc)

Our Partners and Collaborators

Explore our publications, news,
case studies and blogs to learn more.
Please contact us
to discuss your specific needs!